CapsoVision Inc
CV13.810USD
+0.910+7.05%
交易中 （美东）报价延迟15分钟
646.29M总市值
亏损市盈率 TTM
关于 CapsoVision Inc 公司
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
CapsoVision Inc简介
公司代码CV
公司名称CapsoVision Inc
上市日期Jul 02, 2025
CEOWang (Kang-Huai)
员工数量90
证券类型Ordinary Share
年结日Jul 02
公司地址18805 Cox Avenue
城市SARATOGA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编95070
电话14086241488
网址https://www.capsovision.com/
公司代码CV
上市日期Jul 02, 2025
CEOWang (Kang-Huai)
CapsoVision Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Kang-Huai (Johnny) Wang
Mr. Kang-Huai (Johnny) Wang
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.10M
--
Mr. Chen Lung Tsai
Mr. Chen Lung Tsai
Independent Chairman of the Board
Independent Chairman of the Board
115.46K
--
Mr. Wen-Herng Henry King
Mr. Wen-Herng Henry King
Independent Director Nominee
Independent Director Nominee
41.42K
--
Ms. Hui Ying (Patty) Kuo
Ms. Hui Ying (Patty) Kuo
Independent Director
Independent Director
20.71K
--
Mr. Douglas Atkinson
Mr. Douglas Atkinson
Head - Global Sales
Head - Global Sales
--
--
Ms. Heidi Chung Sutardja
Ms. Heidi Chung Sutardja
Director
Director
--
--
Mr. David Garcia
Mr. David Garcia
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Ms. Keri Jorgenson
Ms. Keri Jorgenson
Director of Clinical Operations
Director of Clinical Operations
--
--
Mr. Howard Lee
Mr. Howard Lee
Director
Director
--
--
Mr. Pen-Jung Tseng
Mr. Pen-Jung Tseng
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Kang-Huai (Johnny) Wang
Mr. Kang-Huai (Johnny) Wang
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.10M
--
Mr. Chen Lung Tsai
Mr. Chen Lung Tsai
Independent Chairman of the Board
Independent Chairman of the Board
115.46K
--
Mr. Wen-Herng Henry King
Mr. Wen-Herng Henry King
Independent Director Nominee
Independent Director Nominee
41.42K
--
Ms. Hui Ying (Patty) Kuo
Ms. Hui Ying (Patty) Kuo
Independent Director
Independent Director
20.71K
--
Mr. Douglas Atkinson
Mr. Douglas Atkinson
Head - Global Sales
Head - Global Sales
--
--
Ms. Heidi Chung Sutardja
Ms. Heidi Chung Sutardja
Director
Director
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
FY2023
业务USD
名称
营收
占比
Products (capsules and capsule reading devices)
3.12M
93.97%
Services (cloud-based video delivery and reading services)
200.00K
6.03%
地区USD
名称
营收
占比
United States
2.55M
77.01%
Outside United States
762.00K
22.99%
业务
地区
业务USD
名称
营收
占比
Products (capsules and capsule reading devices)
3.12M
93.97%
Services (cloud-based video delivery and reading services)
200.00K
6.03%
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Harari Eliyahou Et Al
9.19%
Ching-Hang (Shen)
8.52%
Kioxia Corporation
7.36%
CID Greater China Venture Capital Fund III, L.P.
6.67%
Shih-Chang (Stephen Wu)
5.04%
其他
63.22%
持股股东
持股股东
占比
Harari Eliyahou Et Al
9.19%
Ching-Hang (Shen)
8.52%
Kioxia Corporation
7.36%
CID Greater China Venture Capital Fund III, L.P.
6.67%
Shih-Chang (Stephen Wu)
5.04%
其他
63.22%
股东类型
持股股东
占比
Individual Investor
17.40%
Corporation
14.03%
Other Insider Investor
9.19%
Investment Advisor/Hedge Fund
0.42%
Investment Advisor
0.35%
Hedge Fund
0.06%
Research Firm
0.02%
Pension Fund
0.02%
Bank and Trust
0.01%
其他
58.50%
机构持股
更新时间: 9月12日 周五
更新时间: 9月12日 周五
报告期
机构数
持股数
持股占比
持股变动
2025Q3
11
196.14K
0.42%
+171.24K
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Harari Eliyahou Et Al
4.31M
9.21%
+4.31M
--
Jul 02, 2025
Ching-Hang (Shen)
3.91M
8.36%
+3.91M
--
Jul 02, 2025
Kioxia Corporation
3.45M
7.37%
+3.45M
--
Jul 02, 2025
CID Greater China Venture Capital Fund III, L.P.
3.13M
6.68%
+3.13M
--
Jul 02, 2025
Shih-Chang (Stephen Wu)
2.36M
5.05%
+2.36M
--
Jul 02, 2025
Wang (Kang-Huai)
1.10M
2.36%
+1.10M
--
Jul 03, 2025
Harari (Michele)
573.91K
1.23%
+573.91K
--
Jul 02, 2025
Tsai (Chen Lung)
115.46K
0.25%
+115.46K
--
Jul 02, 2025
Geode Capital Management, L.L.C.
24.90K
0.05%
--
--
Aug 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
占比0.01%
Global X Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
CapsoVision Inc的前五大股东是谁？
CapsoVision Inc 的前五大股东如下：
Harari Eliyahou Et Al持有股份：4.31M，占总股份比例：9.21%。
Ching-Hang (Shen)持有股份：3.91M，占总股份比例：8.36%。
Kioxia Corporation持有股份：3.45M，占总股份比例：7.37%。
CID Greater China Venture Capital Fund III, L.P.持有股份：3.13M，占总股份比例：6.68%。
Shih-Chang (Stephen Wu)持有股份：2.36M，占总股份比例：5.05%。
Harari Eliyahou Et Al持有股份：4.31M，占总股份比例：9.21%。
Ching-Hang (Shen)持有股份：3.91M，占总股份比例：8.36%。
Kioxia Corporation持有股份：3.45M，占总股份比例：7.37%。
CID Greater China Venture Capital Fund III, L.P.持有股份：3.13M，占总股份比例：6.68%。
Shih-Chang (Stephen Wu)持有股份：2.36M，占总股份比例：5.05%。
CapsoVision Inc的前三大股东类型是什么？
CapsoVision Inc 的前三大股东类型分别是：
Harari Eliyahou Et Al
Ching-Hang (Shen)
Kioxia Corporation
Harari Eliyahou Et Al
Ching-Hang (Shen)
Kioxia Corporation
有多少机构持有CapsoVision Inc(CV)的股份？
截至2025Q3，共有11家机构持有CapsoVision Inc的股份，合计持有的股份价值约为196.14K，占公司总股份的0.42%。与--相比，机构持股有所增加，增幅为--。
哪个业务部门对CapsoVision Inc的收入贡献最大？
在FY2025Q2，Products (capsules and capsule reading devices)业务部门对CapsoVision Inc的收入贡献最大，创收3.12M，占总收入的93.97%。
